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Abstract
Background: Adherence with tobramycin inhalation solution (TIS) during routine cystic fibrosis (CF) care may differ
from recommended guidelines and affect health care utilization.
Methods: We analyzed 2001-2006 healthcare claims data from 45 large employers. Study subjects had diagnoses
of CF and at least 1 prescription for TIS. We measured adherence as the number of TIS therapy cycles completed
during the year and categorized overall adherence as: low ≤ 2 cycles, medium >2 to <4 cycles, and high ≥ 4
cycles per year. Interquartile ranges (IQR) were created for health care utilization and logistic regression analysis of
hospitalization risk was conducted by TIS adherence categories.
Results: Among 804 individuals identified with CF and a prescription for TIS, only 7% (n = 54) received ≥ 4 cycles
of TIS per year. High adherence with TIS was associated with a decreased risk of hospitalization when compared to
individuals receiving ≤ 2 cycles (adjusted odds ratio 0.40; 95% confidence interval 0.19-0.84). High adherence with
TIS was also associated with lower outpatient service costs (IQR: $2,159-$8444 vs. $2,410-$14,423) and higher
outpatient prescription drug costs (IQR: $35,125-$60,969 vs. $10,353-$46,768).
Conclusions: Use of TIS did not reflect recommended guidelines and may impact other health care utilization.
Background
Over the past 20 years, median life expectancy for patients
with cystic fibrosis (CF) has increased; recent data from
the Cystic Fibrosis Foundation Patient Registry demon-
strated a median survival of 37.4 years among patients in
the United States (US) [1]. These improvements in survi-
val are associated with earlier diagnosis, more active treat-
ment of pulmonary and digestive complications, and a
growing number of effective therapies [2]. One of the con-
sequences of these medical advances is the increased dura-
tion and complexity of daily treatments for CF [3]. As
research in other chronic illnesses has shown, both time
and complexity of daily regimen are associated with lower
rates of adherence [4], and these observations may also be
true for the CF population [5].
In CF, bacterial inflammation and infections of the
lungs are common, particularly those caused by the
pathogen Pseudomonas aeruginosa (P. aeruginosa). By
the age of 18, approximately 80% of individuals with CF
test positive for P. aeruginosa [1,6]. Individuals with CF
and P. aeruginosa infections have twice the risk of hos-
pitalization for acute respiratory exacerbations and twice
the risk of death as those without P.aeruginosa infec-
tions [7,8]. The aminogylycosdies tobramycin, gentaicin
and colistin are active against P. aeruginosa and these
drugs are administered by inhalation, although only
tobramycin inhalation solution (TIS) is approved for
inhalation. The Cystic Fibrosis Pulmonary Guidelines:
Chronic Medications for Maintenance of Lung Health
recommend the chronic use of TIS if P. aeruginosa is
persistently present in airway cultures, regardless of the
severity of the disease, although the recommendation is
strongest in the case of moderate to severe disease [9].
Reported rates of prescribing TIS to eligible patients
are highly variable, ranging from 47-90% [3,10,11]. Esti-
mates from the CF Foundation patient registry suggest
that nearly 58% of individuals with CF and P. aeruginosa
have had TIS prescribed at least once, although there
are no estimates of chronic use [9]. Other estimates of
TIS use have been limited by the lack of data beyond
initial receipt of the medication and the use of self-
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estimates [3,4,12,13].
In the U.S., the majority of patients with CF receive
their health care through a network of over 120 CF care
centers and affiliated programs that are located nation-
wide. CF centers provide multi-disciplinary care teams
of physicians, nurses, social workers, and respiratory
therapists. Approximately 60% of CF patients have their
health care services and products paid for by employer-
based health insurance that is offered to employees and
their dependents as part of the employment benefit
package [1]. Detailed insurance claims are generated for
every prescription drug, hospitalization, and physician
service received by patients with CF and thus claim-
based databases are one of the most comprehensive
sources for assessing the overall health care utilization
of this patient population in the U.S. [14].
The objectives of this study were to: 1) measure
adherence with TIS as documented in prescription
claims data and 2) assess the relationship between use
of TIS and health care utilization, particularly
hospitalizations.
Methods
Data
This study used a research database of health care claims,
the 2001-2006 Medstat MarketScan Commercial Claims
and Encounters and Medicare Supplemental Databases
(Ann Arbor, MI). This national database contains over
500 million claim records per year from individuals with
private health care insurance in the United States. Scien-
tific studies based on this data source have been reported
in more than 75 peer-reviewed articles [15]. The data
come from approximately 45 large employers who self-
insure their employees and dependents. Typically, large
corporations or government entities use self-insurance as
a way to manage their risk pool of sick and healthy
employees rather than hire an insurance company. Self-
insured employers have detailed data on the health care
utilization of their employees and dependents since med-
ical care providers must submit claims for reimburse-
ment for all services rendered.
The MarketScan database offers advantages over raw
administrative claims because data files undergo validity
and editing procedures to ensure high quality and
consistency in fields across years [16]. The data are eval-
uated against population norms, previous year summa-
ries, and validated data subsets. Outliers are flagged and
reviewed for coding or processing errors. Encounter
data describe the individuals who are covered within the
database and are audited at the health plan level and
plans submitting incomplete data are excluded. Diagnos-
tic and procedural codes are compared against validity
algorithms and set to missing values if inconsistent. The
encounter data include age, sex, geographic residence,
and eligibility information. The prescription claims
include the national drug codes, date of purchase, quan-
tity, days’ supply, and expenditure information. The
medical claims contain payment information, diagnoses,
procedure codes, and type of provider. For this analysis,
we pooled annual files to create a dataset of approxi-
mately 12 million people.
Sample
We identified the study sample as individuals who had
at least 2 inpatient or outpatient claims with a diagnosis
of CF using an International Classification of Disease-9
th
Revision-Clinical Modification (ICD-9-CM) code of
277.0x and were continuously enrolled in health insur-
ance with drug coverage for at least 1 year (n = 2,515).
Using at least 2 claims for the diagnosis of CF has been
shown to increase specificity for CF cases by increasing
the probability of identifying true cases in administrative
datasets, although sensitivity is generally low [17]. Indi-
viduals were excluded if they had not used TIS as
described below (n = 1,691) or had undergone lung
transplantation (n = 20).
Measure of TIS utilization
We developed a new measure of adherence with TIS to
reflect the unique administration of this therapy as a
cycle of 28 days on therapy and 28 days off therapy.
Adherence was calculated as the sum of the days’ supply
dispensed during the year divided by 56. Overall adher-
ence categories were defined as: low utilization ≤ 2
cycles, medium utilization > 2 to < 4 cycles, and high
utilization ≥ 4 cycles. These categories were defined
with clinician input and review of TIS utilization data in
the hypothesis generating phase of this study. Adher-
ence, as defined by these annual utilization thresholds,
was measured only during the first year of observation,
and did not include extemporaneously compounded
aerosolized tobramycin.
Measures of health care utilization
Health care utilization was extracted from all-cause
medical claim encounters. Hospitalization was deter-
mined by any admission to an inpatient care setting.
Total costs were summed over the year and categorized
into two main settings of care (i.e., inpatient care and
outpatient care), and prescription drugs. We inflated the
health care cost values to the year 2006 using factors
from the US Bureau of Labor Statistics current data on
the consumer price index [18].
Demographic and Health Measures
We evaluated demographic characteristics, including
age, gender, and the 4 U.S. geographic regions of
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type of health insurance plan (i.e., comprehensive, health
maintenance organization, preferred provider organiza-
tion, and other). In addition, we examined the claims data
of each individual for primary and secondary diagnoses
indicating selected comorbidities. A total burden of
comorbidity score was calculated using the Diagnostic
Cost Group Hierarchical Condition Category (DCG/HCC)
classification system (DxCG, Boston, MA) [19]. The DCG/
HCC model produces a risk score for each person based
on the presence of 189 medical conditions in the diagnosis
fields of claims records. The model uses diagnoses from
all sites of service and imposes hierarchies on the resulting
condition categories prior to calculating risk scores. The
hierarchies identify the most costly manifestation of each
distinct disease and decrease sensitivity of the DCG/HCC
models to coding idiosyncrasies. For ease of interpretation,
we normalized the individual’s scores by the population
average score, and categorized the study population into
two groups, those with less than or average (for the gen-
eral population) comorbidity risk and those with higher
than average risk. In the general population, the DCG/
HCC has shown good predictive validity for death, hospi-
talization, and health care expenditures [20]. In addition,
we searched for two CF-related diagnoses, not included in
the comorbidity score, P. aeruginosa (ICD-9 codes 277.02,
041.7) and Failure to Thrive/Growth Failure (ICD-9 codes
783.41, 783.43).
Data Analysis
For the statistical analyses, we calculated means, fre-
quency distributions and 95% confidence intervals, and
tested group differences using chi-squares and t-tests at
the p < 0.05 level. We reported medians and interquar-
tile ranges for all expenditures and used logistic regres-
sions to estimate the probability of hospitalization.
All statistical analyses were carried out with the SAS
9.1.3 (SAS Institute, Inc., Cary, North Carolina). Addi-
tionally, this study received an exemption waiver from
the University of Massachusetts’s Institutional Review
Board for the use of previously collected and de-identified
data.
Results
The characteristics of the 804 individuals identified
with CF who were receiving TIS therapy are shown in
Table 1. About 43% were adults 18 years of age or
older, 53% were male, and 66% lived in the South or
Midwest region of the U.S. Approximately 12% had dia-
betes mellitus (data not shown) and nearly 35% had a
higher than average comorbidity score. Overall, 56.1% of
the sample had a diagnosis of P. aeruginosa.
Chronic us of TIS was low in subjects with P. aeruginosa
as only 6% were dispensed ≥ 4 cycles per year as shown in
Table 2. TIS usage in the three utilization strata was
similar for subjects with and without the diagnosis of
P. aeruginosa.
In comparison to subjects with high utilization of TIS,
those using fewer than 4 cycles a year were more likely
to be hospitalized as shown in Table 3. However, among
those hospitalized, inpatient costs were similar between
the three utilization strata. Median outpatient costs
(excluding drug costs) were lower among high TIS users
compared to those using fewer cycles. However, median
outpatient prescription drug costs were higher among
high users. TIS represented between 29% and 45% of
total prescription drug costs.
High use of TIS was associated with a decreased risk
of hospitalization relative to low use (Adjusted odds
ratio (AOR) 0.40; 95% CI 0.19-0.84) as shown in
Table 4. In contrast, a higher than average comorbidity
Table 1 Characteristics of cystic fibrosis study population
receiving tobramycin inhalation solution, N = 804
Demographic characteristics %*
Age, years
<6** 13.2
6-10 12.2
11-17 31.5
18-25 22.0
≥26 21.1
Gender
Male 52.7
Female 47.3
Comorbidity score
≤Average 65.3
>Average 34.7
Geographic region
Northeast 12.3
Midwest 27.0
South 39.1
West 21.4
Health Plan Type
Comprehensive 7.6
HMO 23.0
Preferred Provider Organization 49.0
Other Plans 20.4
Selected comorbidity
Pseudomonas aeruginosa 56.1
Failure to thrive/Growth failure 4.4
*percentages may not add up to 100% due to rounding.
**< 6 years of age further divided; 3.9% of patients were < 2 years of age and
9.3% were 2-5 years of age.
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P. aeruginosa (AOR 3.0; 95% CI 2.13-4.32), and a coded
diagnosis of failure to thrive/growth failure (AOR 2.8; 95%
CI 1.09-7.14) were all independently associated with an
increased risk of hospitalization. Age and gender were not
found to be predictive of hospitalization in this analysis.
Discussion
To our knowledge, this is one of the first studies to
assess the link between TIS use in CF patients and
health care utilization as captured in health claims data.
In this study of 804 individuals with CF, 56% were iden-
tified as having P. aeruginosa, although only 6% of those
with P. aeruginosa were dispensed at least 4 cycles dur-
ing the year of observation. These findings are similar to
those found in a previous study of 357 individuals with
CF and P. aeruginosa, where only 4% were utilizing
chronic intermittent TIS according to guidelines [21],
although there was overlap in the study samples.
Rates of aerosolized antibiotic use in CF patients have
been previously reported. Int h eC F FP a t i e n tR e g i s t r y ,
the national average rate of reported use (based on pro-
vider prescribing) was 60.8% (range 17.2-94.7%) in 2001
and 61.8% (range 0-100%) in 2006 [22]. However, these
data were not analyzed by P. aeruginosa status. Analysis
of the Epidemiologic Study of CF database showed that
73.1% of patients with P. aeruginosa and 33.8% of
patients without P. aeruginosa used inhaled tobramycin
from 2003-2005 and that 49.7% vs. 15.9% of all patients
received inhaled tobramycin for chronic vs. exacerbation
use, respectively [23]. Neither of these previous analyses
assessed dispensing or refill history or if inhaled tobra-
mycin was used according to practice guidelines, and
both assessed all formulations of aerosolized tobramycin.
In the pivotal clinical trial of TIS, Ramsey et al. noted
that subjects in the tobramycin group were 26% less
likely to be hospitalized and 36% less likely to be treated
with intravenous antibiotics than subjects in the placebo
group [24]. In the current study, CF subjects with high
utilization (≥ 4 cycles per year) had fewer hospitaliza-
tions than those subjects with medium and low utiliza-
tion; the risk of hospitalization among those with high
utilization was decreased by 60% compared with those
taking 2 or fewer cycles per year. Thus, our findings are
consistent with the clinical trial results, and suggest that
TIS use in routine clinical care and not within a clinical
trial may also be associated with a reduction in hospita-
lizations. This finding deserves further study as the sam-
ple size of CF patients with high utilization was modest
(n = 54) and many factors besides TIS adherence contri-
bute to hospitalization risk.
We noted that while median outpatient costs, exclud-
ing drug costs, were lower for high users, median outpa-
tient drug costs were higher. Previous studies have
sought to examine whether the cost of TIS can be par-
tially offset by reductions in the use of other health care
resources. LeLorier et al. and Iles et al. have shown that
the use of TIS could potentially reduce the use of health
care services, particularly hospitalization and intravenous
antibiotic use (29, 30). Furthermore, while not measured
by studies to date, decreased hospitalization is likely to
result in additional cost saving resulting from fewer dis-
ruptions of work and school as well as improved quality
of life for patients and caregivers.
Table 2 Overall adherence with tobramycin inhalation
solution by P. aeruginosa infection
Low
utilization
≤2 cycles
(n = 570)
Medium
utilization >2
to <4 cycles
(n = 180)
High
utilization
≥4 cycles
(n = 54)
All (N = 804) 71% 22% 7%
With P. aeruginosa (n = 452) 72% 22% 6%
Without P. aeruginosa (n = 352) 70% 23% 7%
Table 3 Health care utilization by overall adherence with tobramycin inhalation solution, N = 804
Low utilization ≤2
cycles (n = 570)
Medium utilization >2 to <4
cycles (n = 180)
High utilization ≥4
cycles (n = 54)
Patients hospitalized (%) 42.9% 40.6% 25.9%
Median inpatient costs, IQR $23,619 $16,814 $20,610
$11,566-55,446 $9,527-41,021 $8,076-64,799
Median outpatient costs, (excludes drug costs) IQR $6,317 $5,463 $4,033
$2,564-14,423 $2,410-13,653 $2,159-8,444
Median outpatient prescription drug costs, IQR $17,850 $35,892 $46,708
$10,353-27,260 $27,482-46,768 $35,125-60,969
% of outpatient prescription drug costs for TIS, median 29% 41% 45%
IQR = interquartile range; TIS = tobramycin inhalation solution.
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be due to several factors. Patients may not have a com-
plete understanding of TIS and its risks and benefits
and they also have several other medications and treat-
ments to complete each day. In addition to the treat-
ment burden, use of TIS may be limited because of
barriers such as taste, portability of the treatment or
inability to pay the coinsurance (31). Although TIS is
recommended for patients with P. aeruginosa infection,
prescribing patterns are not consistent nationally, and
TIS is likely increasingly being used both as part of
early eradication protocols and to treat CF pulmonary
exacerbations. Thus, low utilization or fewer annual
cycles may reflect these practice patterns.
There are some limitations to this study. This study
used pharmacy claims records to measure adherence,
and thus our analysis assessed rates of medication
acquisition rather than medication exposure. However,
research has demonstrated predictive validity for mea-
s u r i n gt h ec u m u l a t i v ee x p o s u r eo fm e d i c a t i o n sw i t h
acquisition data [25]. It should be noted, though, that
studies using electronic data capturing methods have
found a range of adherence rates with some reporting
higher levels of TIS adherence in selected populations
[26]. Second, P. aeruginosa infection and the rate of fail-
ure to thrive may be under-coded due to lack of finan-
cial incentive to add these diagnoses to billing records.
Additionally, the DCG/HCC model has not, to our
knowledge, been previously applied to a CF population.
Thus, its performance as validated in general popula-
tions may vary from what was observed in our study
population. However, there is value to applying a stan-
dard risk-adjustment methodology to minimize the dif-
ferences in comorbidity levels observed in the sample.
In this dataset we do not have an objective measure of
disease severity, such as forced expiratory volume in one
second (FEV1), to correlate lung health with TIS use.
Further, it should be noted that our measure of adher-
ence does not assess all aspects of physician prescribing
patterns (e.g. use of generic tobramycin). Also, this
study population may not be generalizable to the Ameri-
can CF population; although the proportion of males
and adult patients is comparable to that reported to the
Patient Registry in 2007, the distribution of geographic
regions is not comparable to Registry data (1). Fewer
patients from the Northeastern United States were iden-
tified for inclusion in the current study, although the
impact of geographic region on prescribing patterns for
TIS and access to care are unknown. This dataset
reflects patients with private health care insurance and
findings may not be generalizable to patients on public
assistance. Finally, this analysis was limited to one year
of observation and did not assess utilization patterns
after that period.
The value of a dataset derived from administrative
claims data may be unfamiliar to CF clinicians, however,
such data are appropriate for assessing many facets of
quality of care. One particular strength of these data is
the ability to capture medication adherence as measured
through prescription dispensing; in this study, we found
that persistent use of TIS was quite low and deserves
further investigation. We are currently conducting a
randomized controlled trial across 19 CF Care Centers
(iCARE: I Change Adherence and Raise Expectations
Study, NCT01232478) to identify effective strategies that
improve adherence in adolescents with CF.
Conclusions
High utilization of TIS was infrequent yet associated
with a decreased risk of hospitalization. However, the
low utilization of TIS in subjects with P. aeruginosa
noted in this study is of concern. These data suggest
that CF patients may not be using TIS as recommended
by the CF Pulmonary Guidelines. Future studies to
address ways to improve adherence are warranted to
ensure patients can benefit from their chronic
treatments.
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Table 4 Logistic regression of probability of
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Overall adherence with TIS
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Failure to thrive/growth failure 2.8** 1.09-7.14
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residence; **p < 0.05.
AOR = adjusted odds ratio; CI = confidence interval; TIS = tobramycin.
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